Corporate Headquarters
505 Lomas Santa Fe Drive
Suite 270
Solana Beach, CA 92075

(858)345-1494 Tel.

Investor Relations :: Overview

Stock price graph

Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide is the only product currently approved in the United States to treat gastroparesis, and is currently available only in oral and intravenous forms. EVK-001 is a novel formulation of this drug, designed to provide systemic delivery of metoclopramide through intranasal administration.



Events

Aug 13, 2014
Evoke Pharma Second Quarter 2014 Conference Call

May 13, 2014 at 4:00 PM
Evoke Pharma First Quarter 2014 Conference Call

Mar 25, 2014 at 4:30 PM ET
Evoke Pharma Fourth Quarter 2013 Conference Call


Presentations and Posters

Evoke Pharma Presentation at the Aegis Capital Corp. 2014 Healthcare & Technology Conference. September 11, 2014 PDF 1.7 MB  
Evoke Pharma Investor Presentation PDF 1.3 MB  
Texas Tech University Health Sciences Center PDF 622.5 KB  

Recent Releases

Sep 9, 2014
Evoke Pharma Announces the Completion of Enrollment in Its Thorough ECG Study for EVK-001

Sep 4, 2014
Evoke Pharma to Present at the Aegis Capital Corp. 2014 Healthcare & Technology Conference

View all releases »